Editas Medicine Inc (NAS:EDIT)
$ 5.3 -0.13 (-2.39%) Market Cap: 435.86 Mil Enterprise Value: 173.83 Mil PE Ratio: 0 PB Ratio: 1.48 GF Score: 52/100

Editas Medicine Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 06:30PM GMT
Release Date Price: $32.78 (+0.83%)
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning, everyone. My name is Cory Kasimov. I'm a senior biotech analyst at JPMorgan. And it's my pleasure to introduce our next company, Editas. Here to present for Editas is the company's CEO, Cindy Collins. And please note that following Cindy's presentation, there's a breakout across the hall in the Borgia Room.

So with that, I turn it over to Cindy.

Cynthia L. Collins
Editas Medicine, Inc. - CEO, President & Director

Thank you, Cory, and thanks for the invitation to speak here today. Pushing the boundaries of medicine entails risk as well as great promise. This slide tells you all about the risk. At Editas, we strive to make differentiated, transformational medicines for diseases of high unmet need. To accomplish this objective, we are pursuing 2 strategic pillars, in vivo CRISPR medicine and engineered cell medicines. In our in vivo CRISPR medicine portfolio, we are able to leverage AAV-mediating editing with our proprietary

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot